FENCFennec Pharmaceuticals Inc.

1. Sep 17, 2026On September 17, 2026, Fennec Pharmaceuticals Inc. (the “Company”) announced positive results from the investigator-initiated Phase 2 STS-J01 clinical study of PEDMARK® in Japan, which met its primary endpoint and demonstrated significant hearing protection without evidence of interference with cisplatin antitumor …Other event · Form 8-K
2. May 22, 2026On May 21, 2026, Fennec Pharmaceuticals Inc. (the “Company”) announced that new research evaluating PEDMARK® (sodium thiosulfate injection) across multiple patient populations and tumor types will be shared as part of the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting program.Other event · Form 8-K
3. May 18, 2026Compensatory Arrangements of Certain Officers On May 11, 2026, the Compensation Committee of the Board of Directors of Fennec Pharmaceuticals Inc. approved grants of stock options to purchase an aggregate of 50,000 common shares to three new employees under the Company’s 2026 Equity Inducement Plan, with a grant date …Director or officer change · Form 8-K
4. Apr 28, 2026Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers On April 27, 2026, Rostislav Raykov notified Fennec Pharmaceuticals Inc. (the "Company") of his desire to retire from the Company's Board of Directors (the "Board") and that he will not stand for re-election at the …Director or officer change · Form 8-K
5. Apr 22, 2026On April 21, 2026, Fennec Pharmaceuticals Inc. (the “Company”) issued a press release announcing that four abstracts evaluating PEDMARK ® (sodium thiosulfate injection) were accepted for presentation or publication at the 2026 American Society of Clinical Oncology Annual Meeting in Chicago, Illinois.Other event · Form 8-K
6. Apr 7, 2026On April 7, 2026, Fennec Pharmaceuticals Inc. (the “Company”) announced the initiation of an investigator-sponsored study by University of Arizona Cancer Center to evaluate use of PEDMARK ® (sodium thiosulfate injection) in adolescent and young adult and adult patients with head and neck and testicular cancers …Other event · Form 8-K
7. Mar 24, 2026~ Executed on 2025 Clinical Data Strategy to Expand Real-World Validation of PEDMARK ® Across New Tumor Types and Patient Populations Through Independent, Institution-Led Research ~.Earnings release · press release
8. Mar 16, 2026On March 16, 2026, Fennec Pharmaceuticals Inc. (the “Company”) entered into a License Agreement with Cipla Limited and Cipla USA, Inc. (together, “Cipla”) to resolve the litigation between the Company and Cipla relating to Cipla’s application to the U.S. Food and Drug Administration to market a generic version of the …Other event · Form 8-K
9. Mar 4, 2026On March 4, 2026, Fennec Pharmaceuticals Inc. (the “Company”) announced that the Tampa General Hospital Cancer Institute is initiating a study evaluating the real-world clinical utility of sodium thiosulfate injection (PEDMARK ® ) in reducing the risk of ototoxicity in adolescent and young adult and adult cancer …Other event · Form 8-K
10. Feb 20, 2026On February 20, 2026, Fennec Pharmaceuticals Inc. (the “Company”) announced that real-world data supporting the potential use of PEDMARK ® (sodium thiosulfate injection) in adults with head and neck cancers were presented at the 2026 Multidisciplinary Head and Neck Cancers Symposium held February 19–21, 2026.Other event · Form 8-K
11. Dec 9, 2025On December 9, 2025, Fennec Pharmaceuticals Inc. (the “Company”) announced the planned initiation of an investigator-sponsored clinical study (“IST”) to be conducted by City of Hope, a U.S. cancer research and treatment organization, to evaluate PEDMARK ® (sodium thiosulfate injection) for the prevention of …Other event · Form 8-K

Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.